New drug combo shows promise for High-Risk MDS patients heading to transplant
NCT ID NCT03572764
First seen Apr 15, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study is testing a chemotherapy drug called CPX-351 in 20 adults aged 18-70 with higher-risk myelodysplastic syndrome (MDS) who are candidates for a stem cell transplant. The main goal is to see if the drug is safe and tolerable at two different dose levels. Researchers will also track how many patients achieve remission and proceed to transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.